COVID-19 Update: See the latest on our visitor policy here. Learn More
A Phase 1 Study of CG0070 Combined with Nivolumab in Cisplatin Ineligible Patients with Muscle Invasive Bladder Cancer (MIBC)
Investigators aim to evaluate the safety and efficacy of combination neoadjuvant therapy using intravesical CG0070 and IV Nivolumab in cisplatin ineligible patients with MIBC.
To evaluate the safety of combination therapy using intravesical CG0070 and IV nivolumab according to Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0). To assess the changes in the inflammatory status of the tumors after combination therapy
Immunotherapy; Therapy (NOS)
BMS-936558 (Nivolumab); CG0070 (); DDM (); Nivolumab (Opdivo)
Back to top
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.